Opinion|Videos|August 7, 2024
Ideal Goals for Biosimilar Utilization
The panel discusses ideal goals for biosimilar utilization.
Advertisement
Video content above is prompted by the following:
- What are the ideal goals for biosimilar utilization?
- Similar to small molecule brands and generics: does the reference product go away and biosimilars have the great majority of utilization?
- Or does reference product stay on the market with pricing concessions?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
- Rapid Therapeutic Effects Seen With a JAK Inhibitor
September 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
- The Potential Role of Screening for Atrial Fibrillation
September 16th 2025
- Remote Patient Monitoring and Artificial Intelligence
September 16th 2025
- Reassurance in Breast Cancer Survivorship: Adriana Olivo, NP
September 15th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5